Topics

Latest "Wellington Financial" News Stories

03:33 EDT 19th October 2019 | BioPortfolio

Here are the most relevant search results for "Wellington Financial" found in our extensive news archives from over 250 global news sources.

More Information about Wellington Financial on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Wellington Financial for you to read. Along with our medical data and news we also list Wellington Financial Clinical Trials, which are updated daily. BioPortfolio also has a large database of Wellington Financial Companies for you to search.

Showing "Wellington Financial" News Articles 1–25 of 6,500+

Relevant

Evotec: Hedgefonds Wellington Management auf dem Rückzug

Hamburg (www.aktiencheck.de) - Leerverkäufer Wellington Management Company, LLP fährt Netto-Leerverkaufsposition in Aktien der Evotec AG etwas zurück: Die Finanzprofis des Hedgefonds Wellington Man...


Evotec: Rückzug von Leerverkäufer Wellington Management gewinnt an Dynamik

Hamburg (www.aktiencheck.de) - Leerverkäufer Wellington Management Company, LLP senkt Netto-Leerverkaufsposition in Aktien der Evotec AG jetzt stärker: Die Finanzprofis des Hedgefonds Wellington Ma...

Why the Australasian Health Star Rating needs major changes to make it work

Jessica C Lai, Victoria University of Wellington; Alana Harrison, Victoria University of Wellington; Hongzhi Gao, Victoria University of Wellington, and Samuel Becher, Victoria University of Wellington Unhealthy diets cause multiple physical and mental health problems. To help consumers make healthier choices, Australia and New Zealand introduced the voluntary Health Star Rating (HSR) system in 20...


Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington

Bristol-Myers Squibb’s agreement to acquire Celgene for $74 billion is opposed by the New York pharmaceutical company’s largest institutional investor. Wellington Management Group said Wednesday afternoon that while it agrees Bristol should be active in deals that add new science and expand the company’s revenue potential, Wellington “does not believe that the Celgene transaction is a...

Wellington Partners Raises €210M to Invest in European Life Sciences

VC firm Wellington Partners has raised its fifth fund dedicated to investing in life science companies, with a major focus on those located in German-speaking countries.  Wellington Partners has well surpassed its initial target of €150M for its fifth life sciences fund. With a total €210M raised, this new fund is more than double the […] The post Wellington Partners Raises €210M to I...

How Wellington closed its largest fund yet at €210M

String of exits and well-defined European focus helped Wellington Partners close its fifth and largest fund.

Galapagos NV: Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to ...

Wellington Partners Unveils €210m Eurocentric Biotech:Medtech Fund WPLS-V

With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V...    

Wellington Management Opposes Bristol-Myers Squibb's Acquisition Of Celgene

SUMMIT (dpa-AFX) - Bristol-Myers Squibb Co's (BMY) shareholder Wellington Management said that it does not support the U.S. drugmaker's $74 billion acquisition of biotech Celgene Corp.(CELG).Welli...

Wellington Partners Unveils €210m Eurocentric Biotech/Medtech Fund WPLS-V

With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V...    

Waterloo Wellington signs on to Roots of Hope national suicide prevention project

From Mental Health Commission of Canada and Waterloo Region Suicide Prevention Council CAMBRIDGE, Ontario, Aug. 20, 2019 (GLOBE NEWSWIRE) — Today, the Mental Health Commission of Canada (MHCC) welcomed Waterloo Wellington as the seventh community to sign on to its … Continue reading →

Why Wellington Is Unlikely To Kill The Celgene Bristol-Myers Deal

Regina Hodits, General Partner, Wellington Partners

Regina Hodits, General Partner, Wellington Partners

Wellington Partners launch €210m Life Sciences Fund

Galapagos receives transparency notification from Wellington Management Group LLP

Mechelen, Belgium; 7 October 2019; 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Wellington Management Group LLP. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 4 October 2019 from Wellington Management Group LLP, who notified that the 3,445,603 Galapa...

$BMY $CELG Bristol-Myers holder Wellington Management does not support the company’s proposed acquisition of Celgene 8% holder, #1

$BMY $CELG Bristol-Myers holder Wellington Management does not support the company’s proposed acquisition of Celgene 8% holder, #1

Bristol-Myers Squibb investor opposes Celgene deal

Wellington Management says $90bn pharma takeover is too risky and will not broaden revenues

Bristol-Myers Squibb defends Celgene takeover as ‘best path’

Drugmaker has faced pushback from shareholders, including institutional investor Wellington

Confo's €30M growth plan

Why BioGeneration and Wellington picked Belgium’s Confo as their first investment in a GPCR company.

I agree with Wellington on this Bristol-Celgene acquisition. Very hard to support it if you are on the Bristol side. Bristol management hasn't earned it. $BMY $CELG

I agree with Wellington on this Bristol-Celgene acquisition. Very hard to support it if you are on the Bristol side. Bristol management hasn't earned it. $BMY $CELG

Bristol-Myers wins shareholder backing for Celgene buyout

Opposition from Starboard Value and Wellington had lent some drama to the vote, which makes the roughly $74 billion tie-up between the two companies an all but done deal.

Could institutional investors put the kibosh on the $74B Bristol-Celgene deal?

Two major shareholders in BMS – Wellington Management and Starboard Value – said they would not support the deal and saw it as poorly thought out.

Bristol-Myers blockbuster $90bn Celgene deal at risk

Activist Starboard joins Wellington Management joins fight against industry megamerger

Celgene Complications

Is Bristol-Myers Squibb going to buy Celgene or not? Most such deals go through, but the exceptions are big ones (such as Pfizer’s bid for AstraZeneca). The uncertainty has come in because of yesterday’s announcement from Wellington management, the largest institutional holder of BMY (8% of common shares) that they oppose the deal. You can

Venture Firm Wellington Partners Launches $237 Million Life Science Fund

The fund plans to build a portfolio of about 15 to 20 companies, with a focus on novel biotechnology platforms, new therapeutics and medical devices, as well as diagnostics and digital medicine.


Quick Search

News Quicklinks